Q BioMed Insider to Invest up to $30M in the Company Aedesius Holdings Ltd. (AedesiusOne), a privately held global disruption aggregator, enters Into $30M Securities Purchase Agreement with Q BioMed Up front investment of up to $20M with an optional $10M in 6 month warrants Proceeds may be used for deploying contract sales force, advancing pipeline, redeeming outstanding convertible debt and convertible preferred shares and acquiring later-stage asset(s) News provided by Share this article QBIO), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a privately owned United Kingdom based healthcare and technology aggregator. AedesiusOne is run by Geoffrey Fatzinger, our Global Head of Regulatory Affairs. The agreement gives AedesiusOne the opportunity to buy approximately 43% of the outstanding QBIO shares for an aggregate of $30,000,000. The Transaction is structured as an initial investment of $5,000,000 with an additional $15,000,000 by September 30, 2021 with 50% warrant coverage allowing an additional $10,000,000 investment within 120 days. The Unit Price is set at $1.25 per share, a 31% premium to yesterday's closing price. The investor is expected to ultimately take a seat on the Board.